Singapore markets close in 39 minutes
  • Straits Times Index

    3,158.23
    -33.94 (-1.06%)
     
  • Nikkei

    28,508.55
    -591.83 (-2.03%)
     
  • Hang Seng

    28,664.51
    -471.22 (-1.62%)
     
  • FTSE 100

    6,905.33
    +45.46 (+0.66%)
     
  • BTC-USD

    55,130.27
    +950.31 (+1.75%)
     
  • CMC Crypto 200

    1,261.95
    +27.54 (+2.23%)
     
  • S&P 500

    4,134.94
    -28.32 (-0.68%)
     
  • Dow

    33,821.30
    -256.33 (-0.75%)
     
  • Nasdaq

    13,786.27
    -128.50 (-0.92%)
     
  • Gold

    1,781.90
    +3.50 (+0.20%)
     
  • Crude Oil

    62.37
    -0.30 (-0.48%)
     
  • 10-Yr Bond

    1.5620
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,602.11
    -5.46 (-0.34%)
     
  • Jakarta Composite Index

    5,993.24
    -45.08 (-0.75%)
     
  • PSE Index

    6,439.39
    -61.03 (-0.94%)
     

SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against MultiPlan Corporation– MPLN, MPLN.WS, CCXX, CCXX.WS, CCXX.U

Pawar Law Group
·3-min read

NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) -- Pawar Law Group announces a class action lawsuit on behalf of shareholders who purchased shares of MultiPlan Corporation (NYSE: MPLN, MPLN.WS, CCXX, CCXX.WS, CCXX.U) from July 12, 2020 through November 10, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for MultiPlan Corporation investors under the federal securities laws.

To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email info@pawarlawgroup.com for information on the class action.

According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: MultiPlan was losing tens of millions of dollars in sales and revenues to Naviguard, a competitor created by one of MultiPlan’s largest customers, UnitedHealthcare, which threatened up to 35% of the Company’s sales and 80% of its levered cash flows by 2022; sales and revenue declines in the quarters leading up to the Merger were not due to “idiosyncratic” customer behaviors as represented, but rather due to a fundamental deterioration in demand for MultiPlan’s services and increased competition, as payors developed competing services and sought alternatives to eliminating excessive healthcare costs; MultiPlan was facing significant pricing pressures for its services and had been forced to materially reduce its take rate in the lead up to the Merger by insurers, who had expressed dissatisfaction with the price and quality of MultiPlan’s services and balanced billing practices, causing the Company’s to cut its take rate by up to half in some cases; as a result of the foregoing, MultiPlan was set to continue to suffer from revenues and earnings declines, increased competition and deteriorating pricing dynamics following the Merger; as a result of the foregoing, MultiPlan was forced to seek continued revenue growth and to improve its competitive positioning through pricey acquisitions, including through the purchase of HST for $140 million at a premium price from a former MultiPlan executive only one month after the Merger; and as a result of the foregoing, Churchill III investors had grossly overpaid for the acquisition of MultiPlan in the Merger, and MultiPlan’s business was worth far less than represented to investors. According to the suit, these true details were disclosed by a market research firm.

If you wish to serve as lead plaintiff, you must move the Court no later than April 26, 2021. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.

Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
-------------------------------

Contact:
Vik Pawar, Esq.
Pawar Law Group
20 Vesey Street, Suite 1410
New York, NY 10007
Tel: (917) 261-2277
Fax: (212) 571-0938
info@pawarlawgroup.com